-
公开(公告)号：US20150203566A1
公开(公告)日：2015-07-23
申请号：US14577330
申请日：2014-12-19
Applicant: Five Prime Therapeutics, Inc.
Inventor： Li Long , Thomas Brennan
IPC: C07K14/71 , A61K31/337 , A61K33/24 , A61K31/365 , A61K31/513 , A61K31/282 , A61K39/395 , A61K31/704 , A61K38/17 , A61K31/519
CPC classification number: C07K14/71 , A61K31/282 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/475 , A61K31/513 , A61K31/519 , A61K31/555 , A61K31/704 , A61K31/7048 , A61K33/24 , A61K38/179 , A61K38/38 , A61K39/3955 , A61K45/06 , A61K2039/507 , C07K2319/30 , A61K2300/00
Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
Abstract translation: 治疗癌症的方法包括与选自多西紫杉醇，紫杉醇，长春新碱，卡铂，顺铂，奥沙利铂的至少一种另外的治疗剂组合施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子 ，多柔比星，5-氟尿嘧啶（5-FU），亚叶酸，培美曲塞和贝伐珠单抗。 包含FGFR1 ECD和/或FGFR1 ECD融合分子和/或选自多西紫杉醇，紫杉醇，长春新碱，卡铂，顺铂，奥沙利铂，多柔比星，5-氟尿嘧啶（5-FU），亚叶酸， 还提供了培美曲塞和贝伐珠单抗。 在一些实施方案中，剂量包含有用至少一种另外的治疗剂施用FGFR1 ECD和/或FGFR1 ECD融合分子的说明书。
-
公开(公告)号：US20150050273A1
公开(公告)日：2015-02-19
申请号：US14447751
申请日：2014-07-31
Applicant: Five Prime Therapeutics, Inc.
Inventor： Thomas Harding , Kristen Pierce , Namrata Patil , Thomas Brennan , Julie Hambleton
IPC: C07K16/28
CPC classification number: A61K39/3955 , A61K31/337 , A61K31/513 , A61K33/24 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2863 , C07K2317/24 , C07K2317/41 , C07K2317/732 , C07K2317/92 , A61K2300/00
Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Abstract translation: 本发明提供了结合FGFR2IIIb的抗体，其中抗体是非糖基化的。 本发明提供了包含结合FGFR2IIIb的抗体的组合物，其中组合物中至少95％的抗体是非岩藻糖基化的。 在一些实施方案中，提供了治疗癌症的方法，其包括施用非成胶质细胞的抗FGFR2IIIb抗体。
-
公开(公告)号：US12173069B2
公开(公告)日：2024-12-24
申请号：US16982277
申请日：2019-03-19
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US11814431B2
公开(公告)日：2023-11-14
申请号：US16814627
申请日：2020-03-10
Applicant: Five Prime Therapeutics, Inc.
Inventor： Charles Kaplan , Derrick Houser , Luis Borges , Gloria Brattich , David Bellovin , Felicia Kemp , Majid Ghoddusi , Nels P. Nielson , Kathy Miller , Maike Schmidt
IPC: C07K16/28 , A61K39/395 , G01N33/53 , A61P35/00 , G01N33/574 , A61K39/00
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2818 , G01N33/57492 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
-
公开(公告)号：US20230174647A1
公开(公告)日：2023-06-08
申请号：US17845742
申请日：2022-06-21
Inventor： Xiao Min Schebye , Diana Yuhui Chen , Andrew Rankin , Xiaodi Deng , Joseph Toth , Linda Liang , Michelle Minhua Han , Christine Bee , Hong-An Truong , Mark J. Selby , Nils Lonberg , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Alan J. Korman
IPC: C07K16/28 , A61K47/68 , A61P35/00 , A61K39/395 , A61K45/06 , G01N33/563 , G01N33/577
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/6803 , A61P35/00 , C07K16/2827 , G01N33/563 , G01N33/577 , A61K2039/505
Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
-
Patent Agency Ranking
公开(公告)号：US11566076B2
公开(公告)日：2023-01-31
申请号：US16808910
申请日：2020-03-04
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US20230023174A1
公开(公告)日：2023-01-26
申请号：US17773800
申请日：2020-11-11
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Hong XIANG , Siddhartha MITRA
IPC: C07K14/705 , A61P35/00
Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.
-
公开(公告)号：US11559583B2
公开(公告)日：2023-01-24
申请号：US16786158
申请日：2020-02-10
Applicant: Five Prime Therapeutics, Inc.
Inventor： Emma Masteller , Thomas Brennan , David Bellovin , Kevin P. Baker , Brian Wong
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
-
公开(公告)号：US11421034B2
公开(公告)日：2022-08-23
申请号：US16646690
申请日：2018-09-12
Inventor： Katherine E. Lewis , Serena Kimi Perna , Michael Carleton , Ke Xu , Penny Phillips , Dimple Pandya , Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Janine Powers , Ernestine Lee
IPC: C07K16/28 , A61K47/69 , A61K47/64 , A61P35/00 , A61K31/337 , A61K31/513 , A61K31/7068 , A61K39/395 , C12Q1/6886 , A61K39/00
Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
-
公开(公告)号：US20210070862A1
公开(公告)日：2021-03-11
申请号：US16997581
申请日：2020-08-19
Applicant: Five Prime Therapeutics, Inc.
Inventor： Sandeep P. INAMDAR , Helen L. COLLINS , Xiang ZHANG , Hong XIANG
Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bid to human B7-H4 to a subject in need thereof, for example, a cancer patient.
-
-
-
-
-
-
-
-
-
Search Results
138
records
(took 0.023 seconds)
